NY Cannabis Insider has learned that multistate marijuana operator Curaleaf has recalled products in the state twice since December – this after we recently wrote about the company pulling tens of thousands of units from shelves in July.
The previously unreported information came after NY Cannabis Insider submitted a Freedom of Information Law request to the Office of Cannabis Management.
In a December incident, Curaleaf affixed labels to the outer carton of its unflavored cannabis tinctures that depicted a 1:1 ratio of THC to CBD, whereas the description on the back of the packaging stated the correct ratio, which was 20:1.
This affected nearly 4,000 units, as well as more than 300 patients who received certified letters from Curaleaf that read, in part: “Patients may experience additional side effects related to THC such as drowsiness, dry mouth, anxiety or increased euphoria.”
A Curaleaf spokesperson told NY Cannabis Insider the company is “not aware of any patient complaints.”